Beijing AegleStem Technology Co, founded in December 2020, is located in the Daxing part of the Beijing Daxing International Airport Economic Zone, where it has its own complex GMP standard cell drug production facility that covers 3,341 square meters.
The company is dedicated to exploring and researching skin and soft tissue diseases, and has translated and implemented scientific research achievements from Peking Union Medical College Hospital, establishing a long-term scientific research cooperation relationship with the hospital.
Currently, the company has obtained implied consent for clinical trials in systemic sclerosis, localized scleroderma, and diabetic foot ulcers, and has already begun clinical trials.
Adhering to the core values of "caring for life, quality first", the company is gradually realizing its vision of creating the No 1 brand of stem cell therapy for skin and soft tissue diseases in China.